FDA Chelation Warnings Reflect Growth In Bogus OTCs, Supplements
This article was originally published in The Tan Sheet
Executive Summary
FDA says its Oct. 14 warnings about unapproved autism treatment claims for chelation products marketed as OTCs or dietary supplements reflect a growing problem of fraud in consumer health care product marketing
You may also be interested in...
In Brief
Consent decree follows claim warning
Timely 483 Response Can Ease Agency Enforcement Action – FDA Official
A substantive and timely response to a form 483 can help a firm avoid or mitigate further FDA enforcement action, a senior agency official says.
RAPS Annual Conference In Brief
FDA's supplement GMP focus evolves